Cancer Vaccine - Vibrant IP

The dual-phase cancer treatment uses marker genes in normal cells for early detection and precise targeting of cancer cells, improving treatment accuracy.

Categories: Clinical & Laboratory, Human Disease, Pharmaceutical

General Details

The dual-phase cancer treatment system uses two stages to improve cancer care. In the Preparative phase, marker genes are added to normal cells to detect early signs of gene deterioration (e.g., BRCA1, BRCA2). In the Realized phase, these markers help precisely identify and target cancer cells, leading to more effective treatments.

Key benefits include early cancer detection, targeted therapy that minimizes damage to healthy cells, and the combination of chemotherapy with immune boosters for better cancer cell removal. Advanced techniques ensure accurate detection and treatment, while minimizing side effects by protecting healthy cells.

This approach enhances personalized cancer care by using genetic markers and advanced gene techniques to focus treatment on cancer cells while preserving healthy tissue. This method, similar to FDA-approved therapies, offers promising improvements in treatment outcomes and patient quality of life.

If you are interested in Cancer Vaccine, please visit this link.
Patent Portfolio
- US11460406 – “Method for identifying and treating cancer”
- US20210003507 – “Method for Identifying and Treating Cancer”
Data Room Access & Additional Details
Other Public Data Room Materials Available at VIP-3358 Public Data Room for Cancer Vaccine:
- Introductory Materials
- Patent
- Patent File History
- Non-Disclosure Agreement Draft to access more files listed below
Additional Materials (available upon signing a mutual non-disclosure agreement):
- Due Diligence Review
- Technical Workflow of IP
More Information
Pricing guidance for this transaction may be available. All parties interested in the IP above are authorized to contact Spencer Rogers at Vibrant IP, LLC at spencer@vibrantip.com and 415-997-9772.